Welcome to AIMM Therapeutics
AIMM Therapeutics is a privately held research-based biotechnology company which uses proprietary state-of-the-art antibody technology platforms to develop therapeutic human monoclonal antibodies for prevention and treatment of diseases with a high unmet medical need including cancer, infectious-, inflammatory -, and autoimmune diseases. AIMM Therapeutics uses its AIMSelect™ technology to immortalize and select B cells of individuals who produce antibodies with high therapeutic value.
When desired, AIMM antibodies can be further affinity matured in a proprietary AIMProve™ process that does not require molecular engineering.
AIMM Therapeutics also applies its AIMSelect™ and AIMProve™ technologies to generate antibodies from B cells of a proprietary mouse model with a human immunesystem.
Finally, AIMM Therapeutics utilizes a fully site-specific coupling technology, AIMLink™ to generate stable bi-specific antibodies with a defined molecular composition.
We have created a pipeline of high quality monoclonal antibodies specific for pathogenic viruses and bacteria, including Respiratory Syncytial virus, Hepatitis C virus, Cytomegalo virus, Influenza virus, Methicillin resistant Staphylococcus aureus, Clostridium difficile and Streptococcus pneumonia. In addition anti-cancer mabs have been identified.
